Incorporated as a private limited liability company in Nigeria
MeCure Industries PLC Pharmacist Loyalty Program Terms and Conditions
By participating in the MeCure Industries PLC Pharmacist Loyalty Program, you acknowledge that you have read, understood, and agree to these terms and conditions.
MeCure is a leading human therapeutics company in the pharmaceutical industry in Lagos, Nigeria. For more than a decade, the company has tapped the power of new technology and innovation to advance the practice of medicine.
MeCure pioneered the development of novel products based on advances in technology and launched the pharmaceutical industry’s first tablet in a capsule formulation called Liquitab Floatcap. Today, as a leading healthcare company serving millions of patients, MeCure continues to be an entrepreneurial, technology‐driven enterprise dedicated to helping people fight everyday illness.
Our manufacturing network is continuously optimized so that our customers can have full confidence in our supply chain. This is enabled by high-volume, technologically-advanced distribution facilities. These facilities allow us to deliver new products swiftly and reliably. We continually review our capabilities and capacity. This ensures that we can consistently deliver best-in-class products. Our customers know that their end-consumers are receiving high-quality healthcare and wellness pharmaceuticals.
The core and success of our continuous drive for excellence is expressed in the values of our global team. Their commitment and sense of responsibility are derived from the awareness that every product that we make will affect another person’s health. And health is the cornerstone of our dedication to making life better.
MeCure, is committed to supporting initiatives that improve the communities where we operate, provide better access to care for patients, and improve patient outcomes by supporting research that will advance scientific knowledge about our products to generate new medical interventions.
MeCure's Quality Control (QC) team ensures the delivery of high standard products by conducting step by step review. QC, as a centre of excellence, ensures compliance and follows systematic interventions like streamlining SOPs around critical quality parameters, bullet-proofing complex procedures and targeted capacity building.
We believe in
Every single product that rolls out of our factories has our guarantee of world-class quality.
"To contribute to the enrichment of quality of life around Nigeria, through the creation of innovative generic and specialty pharmaceutical drugs and innovative delivery systems."
"Enriching Lives through Innovation in Pharmaceuticals"
We are committed to increasing access to high quality healthcare for people across Nigeria, at every stage of life. We do this by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals.
MeCure's OTC business provides branded products that are intended to prevent illness and promote well-being. These products are part of the increasing shift from treatment to prevention among consumers. This movement is a reflection of people living longer lives, while at the same time expecting continued high quality of life.
MeCure’s exceptional integration of generics enables us to generate a robust pipeline of high-value medicines, with an emphasis on branded generics. Our capabilities have expanded to include tablets, capsules, liquids.
Our superior level of nutraceutical experience is our core competence. We use state-of-the-art manufacturing methods and technology to produce products that exceed expectations, and we leverage that experience to offer our customers the highest quality solutions.
Incorporated as a private limited liability company in Nigeria
Introduced Tropical Pack as the first local producer in Nigeria
Diversified into manufacturing Dry Syrup and medications of Oral Liquid
Introduction of Unit Dosage System from Sarong, Italy
Became one of the largest manufacturers of formulation of Ampicillin Cloxacillin locally and globally
In house product development of 200+ prescription chronic & acute medications
Introduction of Youthberry. Marketed HelloDoc App – a community recognising and promoting the welfare of doctors in Nigeria
ISO 9001:2015 accreditation in process
We are looking for employees whose backgrounds and skill sets are as diverse as the brands that we nurture and grow.
Along with a fast-paced, informal work environment, MeCure offers a competitive compensation and benefits package.
MeCure is an Equal Employment Opportunity/Affirmative Action employer. We affirm the right of every person to participate in all aspects of employment without regard to race, color, religion, national origin, age, disability, creed, gender, marital status, sexual orientation, or status with regard to public assistance, or other protected classifications.
We foster team work and seek individuals that are creative and dedicated to our corporate philosophy. Twelve years of product development, dedication and innovation; support the entrepreneurial work, we pride at MeCure.
A Listing by Introduction means that all the issued and fully paid-up shares of Me Cure Industries Plc (‘the Company’’ or ‘MeCure Industries’) will be listed on the Standard Segment of the Growth Board of NGX Exchange without any additional shares being issued. From this point, all MeCure Industries’ shareholders will be able to trade their shares on the Growth Board of NGX Exchange and members of the public can purchase shares in the Company.
Information about the Listing by Introduction can be found on the investor relations section of the MeCure Industries website Click here for more...
No. MeCure Industries is neither issuing new shares nor raising additional capital. The existing shares are only being listed and made available for trading.
Prior to the Listing by Introduction, there was no public trading market for the ordinary shares of the Company. A valuation analysis and a pricing memorandum were prepared by our financial advisers to provide guidance for the listing price.
Yes. The listing approval procedures for a Listing by Introduction are the same as those for Initial Public Offerings and it can be found on the website of the NGX; here.
Yes. MeCure Industries Plc (previously called MeCure Industries Limited) was incorporated on March 16, 2005 and became a public company on October 27, 2022.
The Board of MeCure will consider all financing options in line with its strategic objectives and when market conditions are conducive.
You can find out the share price on the Company’s website (www.mecure.com) and daily equity pricelist from stockbrokers.
Once the shares are listed on the standard segment of the Growth Board of NGX Exchange, existing shareholders can trade their shares and prospective investors can buy.
The Company’s symbol ticker is MECURE.
Payment of dividends is dependent on several key factors, including our future strategic plans and capital expenditure initiatives. The Company will share a dividend policy when available.
Cordros Registrar provides registrar services to MeCure Industries Plc.
Cordros is licensed and monitored by the Securities and Exchange Commission (SEC). If you have any enquiries regarding your MeCure share records or future corporate actions, please send an email to [insert email of registrar] and the Registrar will address your concerns accordingly.
A share represents part ownership in a company. A shareholder of a public company may
dividends from the company’s profits, participate in its share price performance,
and have the right
to vote at its shareholder meetings.
As a shareholder, you are one of the owners of the company and the number of shares you hold, in proportion to the total number of the Company’s issued shares, is a measure of how much of the company you own.
You can buy or sell shares of MeCure Industries Plc through the service of a stockbroker.
It takes three days for shares traded on the floor of the NGX Exchange to be settled. If you have bought or sold shares through a stockbroker, this triggers a process at CSCS, to ensure a successful delivery of your shares. On the third day after the trade was done [T+3], CSCS will send instructions to the Registrar to amend their records. This is the date on which shares and money are exchanged in the market and is known as the ‘settlement date’. If there is still no change to your CSCS account after this day, please contact your Stockbroker for further assistance.
Lagos, Nigeria - 08 November 2023 – MeCure Industries Plc (“MeCure Industries” or the “Company”) is pleased to announce the successful listing of its shares on the Growth Board of The Nigerian Exchange Limited (“NGX” or “The Exchange”). MeCure Industries is a pharmaceutical company with a track record of enhancing service and product delivery across the pharmaceutical and healthcare industry value chain.
MeCure Industries has satisfied the listing requirements of the Nigerian Exchange Limited and obtained all relevant regulatory approvals. We are now listed in the pharmaceutical sector of the Exchange, with the ticker “MECURE”. A total of 4,000,000,000 (Four Billion) ordinary shares were admitted to trading, representing the total issued share capital of the Company, with one of the largest market capitalisation on the Standard Segment of the NGX’s Growth Board.
Commenting on the listing, the Chairman and Founder, Mr Samir Udani said "The approval to list on the Growth Board of the Nigerian Exchange Limited marks a significant milestone in the journey to achieving our strategic expansion goals and healthy contribution to the national economy through continued reduction of the nation's dependency on import as the primary medium of access to pharmaceutical products."
“By listing on the Nigerian Exchange Limited, we will gain more visibility and expand our reach, thus attracting new investors and strengthening relationships with existing ones," said Mrs Anderline Dukor, Co-CEO of MeCure. "In addition to delivering value to shareholders, we are excited about the opportunities ahead."
Mr Arjun Udani, Co-CEO of MeCure Industries, also added, "The listing marks a new beginning for us as a Company; as it resonates with our commitment to saving lives through innovation and enhancing the health of our consumers by delivering high-quality products, while we maintain sustainable growth of the Company”.
Investors and Analysts
Chief Financial officer
Investor Relations Advisers
Værdi Investor Relations
About MeCure Industries Plc
MeCure Industries is a company principally in the business of manufacturing drugs in Nigeria under two categories namely pharmaceuticals and nutraceuticals. In the pursuit of its primary objective, it adopts the use of modern-day technology and expertise care in services to restore health and save lives through its diverse solutions.
For over a decade, MeCure has developed a reputation for quality and is trusted by its stakeholders (customers, distributors, suppliers, shareholders, employees, etc.). Growth has been demonstrated through historical revenue and market share growth, backed by an experienced management team with over 150 years’ experience across multiple disciplines with a deep understanding of the pharmaceutical industry.
NGX Ticker: MECURE
MeCure Industries Plc Unveils Ground breaking Smartphone Track & Trace Solution, Fortifying the Pharmaceutical Supply Chain and Elevating Patient Safety Standards
Lagos, Nigeria — 8th January 2024 — MeCure Industries Plc is pleased to announce the official implementation of its Track & Trace solution, a program with cutting edge technology ensuring product safety for our customers.
Given the current pharmaceutical governance landscape, the industry faces a dual imperative: ensuring the accessibility of life-saving medications while mitigating potential threats such as falsification. The Track & Trace solution emerges as a pivotal solution, playing a critical role in preventing the infiltration of counterfeit drugs into the healthcare supply chain.
These counterfeit drugs pose a profound risk to public health in the form of incorrect ingredients, improper dosages, or deleterious substances. The ramifications of consuming such falsified medicines span from therapeutic inefficacy to life-threatening complications. Through the comprehensive implementation of a Track & Trace Solution, every stage of a drug's trajectory becomes traceable and verifiable. MeCure Track & Trace enabled brands are impossible to counterfeit.
At its essence, Track & Trace Solution entails the meticulous monitoring and documentation
of the complete journey of a pharmaceutical product, commencing from its manufacturing
facility to the ultimate recipient. This transparency facilitates the prompt identification of
potential issues or discrepancies, thereby enabling timely corrective actions. Any suspicious
deviation in the supply chain or an unauthorized alteration of product information can be
flagged by the Track & Trace program for the stakeholders to intervene expeditiously, curtailing
the dissemination of counterfeit drugs and safeguarding unsuspecting consumers. This
amplifies the efficiency of supply chain management and, more importantly, establishes a
formidable deterrent against the falsification of medicines. It is poised to serve as a beacon
public health, guaranteeing that patients receive authentic, life-saving treatments.
Track & Trace Solution also enhances collaboration among diverse stakeholders in the pharmaceutical supply chain, including manufacturers, distributors, and regulatory bodies. Shared access to a standardized, traceable data system enhances communication and cooperation, creating a unified front against the menace of falsified medicines.
MeCure, a prominent Nigerian pharmaceutical manufacturer in collaboration with ACG
Inspection, a globally recognized Track & Trace Solution provider, has demonstrated
unwavering commitment to the regulator by elevating industry standards on patient safety
through offering authentication of each product with just a click on any smartphone.
MeCure Industries Plc — Track and Trace Solution Press Release
NGX Ticker: MECURE
18 brands within the MeCure portfolio are currently Track & Trace enabled, and all of its 50+ brands will be traceable by the end of the first quarter of 2024.
MeCure Industries PLC extends its sincere appreciation to the Director General of NAFDAC, Prof. Moji Christianah Adeyeye, for her visionary leadership in consistently staying at the forefront of innovative Solutions such as Track & Trace. Her dedication reflects a profound commitment to advancing better and safer healthcare standards in Nigeria.
Investors and Analysts
Chief Financial officer
Investor Relations Advisers
Værdi Investor Relations
Track & Trace in healthcare logistics is the practice of monitoring and tracing the movement of pharmaceutical products throughout the supply chain. This system ensures real-time/ near real-time visibility, enabling efficient regulatory compliance, and rapid response to recalls. Serialization, a pivotal process in healthcare logistics, involves tagging each product with a unique 12-digit serial number. This unique identifier is printed on the product's packaging, forming the basis for precise tracking and tracing throughout the supply chain.
NAFDAC and GS1 Nigeria are playing a pivotal role to encourage local manufacturers implement Track & Trace program with guidelines/regulations. Their objective is to facilitate the harmonization of critical tracking events and key data elements across the different supply chain entities thus enabling a more transparent healthcare supply chain. The heightened transparency not only aligns with regulatory requirements but also cultivates increased patient trust in the healthcare system.
In addition to enhancing supply chain visibility and ensuring product authenticity, the Track & Trace solution also reduces the risk of errors, improves inventory management, and helps in compliance with regulatory requirements while enabling quicker responses to issues such as recalls.
Numerous African nations, such as Ghana, South Africa, Uganda, Zambia, and Botswana, are actively working on drafting their traceability strategies and implementing regulatory guidelines to streamline and harmonize their healthcare supply chains.
The global standards followed by this regulation will harmonize data exchange across the different supply chain actors, thus increasing supply chain visibility. This, in turn, reduces the susceptibility of the Nigerian pharma supply chain ecosystem to counterfeit drugs.
In the event of a recall or product withdrawal, the Track & Trace solution allows for rapid identification and isolation of affected items. This helps to minimize the impact on consumers and ensures regulatory compliance.
Track & Trace and serialization are extremely crucial for post-marketing surveillance and pharmacovigilance activities. They help in efficient and precise recall management of affected batches, thus making the Nigerian healthcare landscape nimble in responding to and reporting adverse events and product quality issues, mitigating patient risks in the process.
The solution has been implemented with robust security measures, including encryption, authentication, and access controls, to ensure the security and integrity of the tracked data. To reinforce this, periodic audits and compliance checks will be conducted to maintain data quality.
MeCure, a leading Nigerian pharmaceutical manufacturer, demonstrated its ongoing commitment to NAFDAC, by compliance towards patient safety and enhancing industry standards in the Nigerian pharmaceutical landscape by releasing Track & Trace enabled brands into the market that can be authenticated by a smartphone.
You can access the Track & Trace information by scanning the unique code provided on the product packaging using the designated mobile application by following the prompted steps on your phone.
All you need is a smartphone.
The Track & Trace solution provides information on the pack origination and the quality report of the batch. It also encourages you to share any feedback on the product and adverse effects, if any, directly to the manufacturer.
Yes, you can! We advise the use of the Track & Trace solution to verify the authenticity of product before purchase.
Registration is not mandatory for basic access.